aP v/s wP

MYTH VS. REALITY

3 Things You've Been Told About Vaccines
— And Why They're Misleading

Common misconceptions about whole-cell pertussis vaccines — explained with scientific evidence.

✗ MYTH #1

"aP Vaccines Are Better"

THE MYTH CLAIMS:

⚠️ aP vaccines contain only 2–5 bacterial fragments

THE REALITY:

Complete Stimulation = Complete Protection

✅ EasySix uses 3,000+ bacterial antigenic components
✅ Your child's immune system is trained to fight the entire bacteria — not just selected pieces

"Less pain ≠ More protection. A mild sore arm is your child's immune system building an army — that's science working, not a side effect."

✗ MYTH #2

"Fewer Antigens Are Enough"

THE MYTH CLAIMS:

⚠️ A few selected antigens can provide the same immune training as whole-cell vaccines
⚠️ Broader antigen exposure does not matter

THE REALITY:

✅ EasySix contains a whole-cell pertussis component with 3,000+ antigenic components
✅ Broad antigen exposure supports broad immune stimulation
✅ Whole-cell vaccines more closely resemble natural bacterial exposure

"Would you protect your home with 3 locks — or with a full security system?"

✗ MYTH #3

"Fever After Vaccination Means Something is Wrong"

THE MYTH CLAIMS:

⚠️ Fever after vaccination is a sign of illness
A child should not develop fever after vaccination
⚠️ Mild fever means the vaccine is not being tolerated wellantigen exposure does not matter

THE REALITY:

✅ Mild fever can be a normal response following vaccination
✅ It reflects the body's natural immune response to the vaccine
✅ Such reactions are generally short-lived, while the protection developed is long term

"The science behind mild fever post-vaccination is well established — it is a sign of strength, not weakness."

wP based vaccines provides better immunity even after a decade (new study from Canada)

GLOBAL HEALTH ALERT

Pertussis is Back. Worse Than Ever.

Despite widespread vaccination, pertussis cases are surging globally — and the data points to one clear reason: vaccines that stop symptoms but not infection.

GLOBAL HEALTH ALERT

Pertussis is Back. Worse Than Ever.

Global pertussis resurgence highlights the need for vaccines that support broader and longer-lasting immune protection.

🚨

Pertussis Resurgence — A Global Crisis in High-Vaccination Countries

Despite high coverage with acellular vaccines, Bordetella pertussis (Whooping Cough) is experiencing a post-pandemic global resurgence across many countries.

United States

~14×

35,435 cases in 2024 vs 7,063 in 2023 · >5× increase · 6,600 cases Jan–Mar 2025

🇬🇧

England (UK)

~100×

14,905 cases in 2024 vs 856 in 2023 · 1,641% increase · Peak 2024

🇦🇺

Australia

~26×

>57,000 cases in 2024 · Highest since 1991 · National outbreak declared

🇪🇺

Europe

~30×

~60,000 cases during 2023–24 · ~10-fold increase vs 2021–22

🇰🇷

South Korea

~31×

52,651 cases during 2024–25 · Peak observed July 2024

📊 Latest Pertussis Resurgence Data — Key Countries

Country

Latest Resurgence Data

Key Highlight

🇺🇸 United States

35,435 cases in 2024 vs 7,063 in 2023

>5X increase; 6,600 cases reported during Jan–Mar 2025

🇬🇧 England

14,905 cases in 2024 vs 856 in 2023

1,641% increase

🇦🇺 Australia

>57,000 cases in 2024

Highest number since 1991

🇪🇺 Europe

~60,000 cases during 2023–24

~10-fold increase vs 2021–22

🇰🇷 South Korea

52,651 cases during 2024–25

Peak observed in July 2024

Impact of aP vaccines on spread of Pertussis virus

📉

Declining Vaccination Coverage

Declining routine immunization has increased the number of susceptible children worldwide.

⏳

Waning Immunity from aP Vaccines

Protection from acellular pertussis vaccines may decline over time, allowing infection and transmission.

🦠

Pathogen Evolution

Genetic changes in Bordetella pertussis — particularly the emergence of Pertactin-deficient strains selected by aP vaccine pressure — may further impact vaccine effectiveness and drive community spread.

🌍 WHO Position — Recommended Routine Immunization (Updated December 2025) · P.6/30

"Available evidence indicates that licensed aP and wP vaccines have equivalent initial effectiveness in preventing disease in the first year of life, but there is more rapid waning of immunity, and possibly reduced impact on transmission, with aP relative to wP vaccines."

WHO recommends wP based vaccines to prevent epidemics

FOR HEALTHCARE PROFESSIONALS

Evidence-Based Medicine Demands an Evidence-Based Choice

Understanding the scientific rationale behind broad antigenic exposure and whole-cell pertussis technology.

🛡️

Elicits a Robust Immune Response

Broader protection through activation of both mucosal and systemic immunity, supporting defense at the site of infection and beyond.

⚡

Strong Th1/Th17 Immune Response

Induces a Th1/Th17 response that closely mimics natural infection, promoting durable immune memory and broad antigenic coverage.

🧬

Strong Secretory IgA & Tissue-Resident Memory T Cells

Promotes secretory IgA and tissue-resident memory T cells (TRM), strengthening first-line defense and supporting long-term immune surveillance.

EasySix provides Th1 Th17 polarization that leads to longer protection

CLINICAL EVIDENCE

Clinically Proven. Rigorously Tested.

Validated through Phase I and Phase II/III clinical studies in India.

Phase I — Safety & Tolerability

Safety study | India

24 healthy infants

No serious adverse events

Safe & well tolerated

Phase II/III — Immunogenicity & Safety

Comparative study | India

272 infants enrolled

Comparable safety profile

Non-inferior immunogenicity

🛡️

All 10 Antigens —Seroconversion Achieved

Protective immune response achieved across all 10 vaccine antigens.

📋

AE Profile —Comparable & Transient

Adverse event profile comparable to comparator vaccine.

📄

Peer-reviewed Evidence Published in Vaccine (Elsevier, 2018) — View Publication →

SIDE BY SIDE — NO MARKETING. JUST FACTS.

aP vs wP —No Marketing. Just Facts.

An honest, evidence-based comparison of acellular vs whole-cell pertussis vaccines.

Feature

💊 aP Containing vaccine

🛡️ EasySix contains wP

Pertussis Antigens

2–5 selected antigens

✅ 3,000+ natural antigens

Immune Breadth

❌ Narrow

✅ Broad — mimics natural exposure

Prevents Disease

✅ Yes

Prevents Infection & Spreading

❌ No

✅ Yes

Efficacy Over Time

📉 Declining every year

✅ Durable

Bacterial Strain Evolution / Escape

⚠️ Creates PRN-deficient strains

✅ No strain escape — 3,000+ antigens

Reconstitution Required

⚠️ Yes — error risk

✅ No — fully liquid

HERD Immunity

❌ Vaccinated children still spread

✅ Reduces transmission

aP vaccines do not prevent natural transmission of the virus

3 Things You've Been Told About Vaccines— And Why They're Misleading

"aP Vaccines Are Better"

"Fewer Antigens Are Enough"

"Fever After Vaccination Means Something is Wrong"

Pertussis is Back. Worse Than Ever.

Pertussis is Back. Worse Than Ever.

Pertussis Resurgence — A Global Crisis in High-Vaccination Countries

Declining Vaccination Coverage

Waning Immunity from aP Vaccines

Pathogen Evolution

Evidence-Based Medicine Demands an Evidence-Based Choice

Elicits a Robust Immune Response

Strong Th1/Th17 Immune Response

Strong Secretory IgA & Tissue-Resident Memory T Cells

Clinically Proven. Rigorously Tested.

Phase I — Safety & Tolerability

Phase II/III — Immunogenicity & Safety

All 10 Antigens —Seroconversion Achieved

AE Profile —Comparable & Transient

Peer-reviewed Evidence Published in Vaccine (Elsevier, 2018) — View Publication →

aP vs wP —No Marketing. Just Facts.

Complete Protection Was Always the Right Choice.

3 Things You've Been Told About Vaccines
— And Why They're Misleading

Complete Protection Was Always
the Right Choice.